1. Home
  2. CNM vs UTHR Comparison

CNM vs UTHR Comparison

Compare CNM & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CNM
  • UTHR
  • Stock Information
  • Founded
  • CNM 1996
  • UTHR 1996
  • Country
  • CNM United States
  • UTHR United States
  • Employees
  • CNM N/A
  • UTHR N/A
  • Industry
  • CNM Durable Goods
  • UTHR Biotechnology: Pharmaceutical Preparations
  • Sector
  • CNM Consumer Discretionary
  • UTHR Health Care
  • Exchange
  • CNM Nasdaq
  • UTHR Nasdaq
  • Market Cap
  • CNM 9.9B
  • UTHR 20.7B
  • IPO Year
  • CNM 2021
  • UTHR 1999
  • Fundamental
  • Price
  • CNM $50.55
  • UTHR $461.49
  • Analyst Decision
  • CNM Buy
  • UTHR Buy
  • Analyst Count
  • CNM 11
  • UTHR 12
  • Target Price
  • CNM $60.64
  • UTHR $495.08
  • AVG Volume (30 Days)
  • CNM 2.0M
  • UTHR 586.0K
  • Earning Date
  • CNM 12-02-2025
  • UTHR 10-29-2025
  • Dividend Yield
  • CNM N/A
  • UTHR N/A
  • EPS Growth
  • CNM 7.24
  • UTHR 16.08
  • EPS
  • CNM 2.25
  • UTHR 26.38
  • Revenue
  • CNM $7,740,000,000.00
  • UTHR $3,128,400,000.00
  • Revenue This Year
  • CNM $4.45
  • UTHR $13.68
  • Revenue Next Year
  • CNM $4.43
  • UTHR $5.63
  • P/E Ratio
  • CNM $22.63
  • UTHR $17.02
  • Revenue Growth
  • CNM 11.02
  • UTHR 13.50
  • 52 Week Low
  • CNM $41.64
  • UTHR $266.98
  • 52 Week High
  • CNM $67.18
  • UTHR $479.50
  • Technical
  • Relative Strength Index (RSI)
  • CNM 38.88
  • UTHR 64.55
  • Support Level
  • CNM $49.97
  • UTHR $444.04
  • Resistance Level
  • CNM $51.56
  • UTHR $456.41
  • Average True Range (ATR)
  • CNM 1.44
  • UTHR 15.02
  • MACD
  • CNM -0.08
  • UTHR 1.21
  • Stochastic Oscillator
  • CNM 10.69
  • UTHR 75.44

About CNM Core & Main Inc.

Core & Main is a leading specialty distributor with a focus on water, wastewater, storm drainage, and fire protection products. The company provides solutions to municipalities, private water companies, and professional contractors across municipal, nonresidential, and residential end markets. The company's specialty products and services are used in the maintenance, repair, replacement, and construction of water and fire protection infrastructure.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

Share on Social Networks: